

**Erika Rijavec**

Nazionalità: Italiana



Data di nascita:

Genere: Femminile

✉ Indirizzo e-mail:

✉ Indirizzo e-mail:

📍 Indirizzo:

📍 Indirizzo:

ESPERIENZA LAVORATIVA

Dirigente medico a tempo indeterminato*U.O.C. Oncologia Medica presso Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico* [01/06/2019 – Attuale]

Città: Milano

Attività ambulatoriale e di Day Hospital

Dirigente medico a tempo determinato*U.O.C. Oncologia Medica presso Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico* [16/02/2019 – 31/05/2019]

Città: Milano

Paese: Italia

Attività ambulatoriale e di Day Hospital.

Dirigente medico a tempo determinato*U.O.S. Tumori Polmonari, presso IRCCS Azienda Ospedaliera Universitaria San Martino - IST* [16/07/2015 – 15/02/2019]

Città: Genova

Attività ambulatoriale, di Day Hospital e di degenza

Ricercatore laureato senior*U.O.S. Tumori Polmonari, presso IRCCS Azienda Ospedaliera Universitaria San Martino - IST* [01/12/2010 – 15/07/2015]

Città: Genova

Paese: Italia

Attività ambulatoriale, di Day Hospital e di degenza

Incarico professionale nell'ambito di progetto di ricerca

Istituto Nazionale per la ricerca sul Cancro – Oncologia Medica A [01/12/2009 – 30/11/2010]

Città: Genova

Paese: Italia

Attività ambulatoriale, di Day Hospital e di degenza

ISTRUZIONE E FORMAZIONE

Specializzazione in Oncologia (Tesi: "Studio di fase II randomizzato con docetaxel vs docetaxel + gemcitabina in pazienti anziani affetti da tumore polmonare non a piccole cellule in stadio avanzato (ATOM 017)" votazione 70 cum laude

Università degli Studi di Udine

Indirizzo: Udine (Italia)

Esame di Stato per l'Abilitazione all'Esercizio della Professione Medica in data 15/02/2006

Laurea in Medicina e Chirurgia (Tesi: "Timidina fosforilasi e carcinoma mammario: implicazioni terapeutiche della modulazione enzimatica") (votazione 110/110) il 21/10/2005

Facoltà di Medicina dell'Università degli Studi di Udine

Iscrizione all'Ordine dei Medici e Chirurghi della Provincia di Udine (n. d'iscrizione 04864)
[01/03/2006 – Attuale]

Maturità scientifica (votazione 93/100) (Luglio 1999)

Liceo Scientifico N. Copernico

Indirizzo: Udine (Italia)

COMPETENZE LINGUISTICHE

Lingua madre:

italiano

Altre lingue:

inglese

ASCOLTO C1 LETTURA C2 SCRITTURA C1

PRODUZIONE ORALE C1 INTERAZIONE ORALE C1

PUBBLICAZIONI

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.

[2021]

Indini A, Rijavec E, Grossi F.

Cancers (Basel). 2021 Apr 9;13(8):1794.

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.

[2021]

J Immunother Cancer. 2021 Apr;9(4):e002421

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, **Rijavec E**, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Grava L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficarella C, Porzio G, Pinato DJ.

The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.

[2021]

Viruses. 2021 Mar 19;13(3):508.

Ghidini M, Indini A, **Rijavec E**, Bareggi C, Cattaneo M, Tomasello G, Galassi B, Gambini D, Grossi F.

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.

[2021]

Int J Mol Sci. 2021 Mar 5;22(5):2628.

Indini A, **Rijavec E**, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Bareggi C, Galassi B, Gambini D, Grossi F.

Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.

[2021]

Expert Rev Anticancer Ther. 2021 Mar 28:1-9.

Rijavec E, Indini A, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Grossi F.

A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday.

[2021]

Melanoma Res. 2021 Apr 1;31(2):190-193.

Indini A, **Rijavec E**, Mandalà M, Castiglioni S, Beltramo G, Grossi F.

Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars.

[2021]

Expert Opin Pharmacother. 2021 Feb 12:1-9.

Ghidini M, Indini A, Nigro O, Polito S, **Rijavec E**, Petrelli F, Tomasello G.

Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study. Cancer.

[2021]

Cancer. 2021 Apr 1;127(7):1091-1101.

Indini A, Cattaneo M, Ghidini M, **Rijavec E**, Bareggi C, Galassi B, Gambini D, Ceriani R, Ceriotti F, Berti E, Grossi F.

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.

[2021]

Eur J Cancer. 2020 Nov 16;142:18-28.

Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, **Rijavec E**, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A.

Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.

[2020]

Clin Breast Cancer. 2020 Sep 6:S1526-8209(20)30216-0.

Coco S, Boccardo S, Mora M, Fontana V, Vanni I, Genova C, Alama A, Salvi S, Dal Bello MG, Bonfiglio S, **Rijavec E**, Sini C, Barletta G, Biello F, Carli F, Cavalieri Z, Burrafato G, Longo L, Ballestrero A, Grossi F.

Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts.

[2020]

Eur J Cancer. 2020 Nov;140:161-162

Indini A, **Rijavec E**, Ghidini M, Cattaneo M, Grossi F.

Coronavirus infection and immune system: An insight of COVID-19 in cancer patients

[2020]

Crit Rev Oncol Hematol. 2020 Sep;153:103059.

Indini A, **Rijavec E**, Ghidini M, Bareggi C, Cattaneo M, Galassi B, Gambini D, Grossi F.

Novel treatment strategies for early-stage lung cancer: the oncologist's perspective.

[2020]

J Thorac Dis. 2020 Jun;12(6):3390-3398.

Indini A, **Rijavec E**, Bareggi C, Grossi F.

Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic.

[2020]

Eur J Cancer. 2020 Aug;135:47-50.

Indini A, **Rijavec E**, Ghidini M, Cattaneo M, Grossi F.

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 .

[2020]

Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221.

Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, **Rijavec E**, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G.

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.

[2020]

Eur J Cancer. 2020 Jul;134:19-28.

Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, **Rijavec E**, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A.

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis.

[2020]

Cancers (Basel). 2020 Apr 18;12(4):998.

Indini A, Petrelli F, Tomasello G, **Rijavec E**, Facciorusso A, Grossi F, Ghidini M.

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.

[2020]

Expert Opin Pharmacother. 2020 Jun;21(8):931-940.

Indini A, **Rijavec E**, Ghidini M, Bareggi C, Gambini D, Galassi B, Antonelli P, Bettio G, Di Nubila C, Grossi F.

Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

[2020]

Cancers (Basel). 2020 Feb 27;12(3):546.

Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, **Rijavec E**, Garassino MC, Grossi F, Tomasello G.

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.

[2020]

Front Immunol. 2020 Feb 7;11:125.

Ottonello S, Genova C, Cossu I, Fontana V, **Rijavec E**, Rossi G, Biello F, Dal Bello MG, Tagliamento M, Alama A, Coco S, Boccardo S, Vanni I, Ferlazzo G, Moretta L, Grossi F, Mingari MC, Carrega P, Pietra G.

Immune related adverse events and response to immunotherapy: Focus on corticosteroids.

[2020]

Lung Cancer. 2020 Jul;145:225.

Indini A, Rijavec E, Grossi F.

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.

[2020]

Clin Transl Oncol. 2020 Sep;22(9):1603-1610.

Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, **Rijavec E**, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegrì F, Genova C, Montecucco F.

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.

[2020]

Expert Rev Respir Med. 2020 Apr;14(4):367-383.

Genova C, Rossi G, Tagliamento M, **Rijavec E**, Biello F, Cerbone L, Zullo L, Grossi F.

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.

[2019]

Cancers (Basel). 2019 Dec 19;12(1):17.

Rijavec E, Coco S, Genova C, Rossi G, Longo L, Grossi F.

Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

[2020]

J Nucl Med. 2020 Jul;61(7):990-998.

Rossi G, Bauckneht M, Genova C, **Rijavec E**, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambucetti G, Lopci E, Morbelli S, Grossi F.

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

[2019]

Int J Mol Sci. 2019 Nov 1;20(21):5452.

Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, **Rijavec E**, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, Fusco N.

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

[2019]

J Clin Med. 2019 Oct 1;8(10):1566.

Genova C, Boccardo S, Mora M, **Rijavec E**, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, Grossi F.

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

[2019]

Clin Exp Metastasis. 2019 Oct;36(5):449-456.

Carbone F, Grossi F, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, **Rijavec E**, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegrì F, Genova C, Montecucco F.

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.

[2019]

Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358.

Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, **Rijavec E**, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegrì F, Genova C, Montecucco F.

Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.

[2019]

Lung Cancer. 2019 Aug;134:121-126.

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, **Rijavec E**, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer).

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.

[2019]

J Clin Med. 2019 Jul 10;8(7):1011.

Alama A, Coco S, Genova C, Rossi G, Fontana V, Tagliamento M, Giovanna Dal Bello M, Rosa A, Boccardo S, **Rijavec E**, Biello F, Longo L, Cavalieri Z, Bruzzo C, Grossi F.

Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds.

[2019]

Expert Opin Investig Drugs. 2019 Jun;28(6):513-523.

Tagliamento M, Genova C, Rossi G, Coco S, **Rijavec E**, Dal Bello MG, Boccardo S, Grossi F, Alama A.

Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus.

[2019]

Immunotherapy. 2019 Jul;11(10):873-879.

Tagliamento M, Grossi F, Paolino S, **Rijavec E**, Genova C, Rossi G, Biello F, De Maria A.

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.

[2019]

Cancers (Basel). 2019 Mar 28;11(4):441.

Coco S, Bonfiglio S, Cittaro D, Vanni I, Mora M, Genova C, Dal Bello MG, Boccardo S, Alama A, **Rijavec E**, Sini C, Rossella V, Barletta G, Biello F, Truini A, Bruzzo C, Gallo M, Lazarevic D, Ballestrero A, Grossi F.

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

[2019]

J Transl Med. 2019 Mar 8;17(1):74.

Dal Bello MG, Filiberti RA, Alama A, Orenco AM, Mussap M, Coco S, Vanni I, Boccardo S, **Rijavec E**, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F.

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

[2019]

Cancers (Basel). 2019 Jan 21;11(1):125.

Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G, Mingari MC, Cossu I, **Rijavec E**, Leggieri A, Di Perri G, Dal Bello MG, Coco S, Boccardo S, Ferlazzo G, Grossi F, D'Avolio A.

Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.

[2018]

Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062.

Tagliamento M, Genova C, **Rijavec E**, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F.

The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.

[2018]

Expert Opin Pharmacother. 2018 Dec;19(17):1969-1976.

Rossi G, Alama A, Genova C, **Rijavec E**, Tagliamento M, Biello F, Coco S, Dal Bello MG, Boccardo S, Grossi F.

CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.

[2018]

Expert Opin Biol Ther. 2018 Jul;18(7):829-835

Tagliamento M, **Rijavec E**, Barletta G, Biello F, Rossi G, Grossi F, Genova C.

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.

[2018]

Oncologist. 2018 Aug;23(8):936-942

Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, **Rijavec E**, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P.

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.

[2018]

Lung Cancer. 2018 Mar;117:64-69

Grossi F, Genova C, **Rijavec E**, Barletta G, Biello F, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.

Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?

[2017]

J Thorac Dis. 2017 Nov;9(11):4300-4304

Genova C, **Rijavec E**, Grossi F.

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.

[2017]

Oncotarget. 2017 Aug 2;8(40):68627-68640

Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, **Rijavec E**, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F.

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

[2018]

Clin Lung Cancer. 2018 Jan;19(1):93-104

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, **Rijavec E**, Cecere F, Spitaleri G, Bria E, Novello S.

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.

[2017]

Int J Mol Sci. 2017 May 11;18(5).

Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, **Rijavec E**, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, Grossi F.

Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: (18)F-FDG PET/CT Study.

[2017]

J Nucl Med. 2017 Nov;58(11):1764-1769.

Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, **Rijavec E**, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, Grossi F.

Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.

[2017]

Expert Opin Investig Drugs. 2017 May;26(5):551-561

Rijavec E, Genova C, Barletta G, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Vanni I, Boccardo S, Alama A, Grossi F.

Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.

[2017]

Expert Opin Drug Saf. 2017 May;16(5):573-585

Genova C, Rossi G, **Rijavec E**, Biello F, Barletta G, Tagliamento M, Grossi F.

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report.

[2016]

Medicine (Baltimore). 2016 Nov;95(48):e5447

Vanni I, Coco S, Bonfiglio S, Cittaro D, Genova C, Biello F, Mora M, Rossella V, Dal Bello MG, Truini A, Banelli B, Lazarevic D, Alama A, **Rijavec E**, Barletta G, Grossi F.

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.

[2017]

Br J Cancer. 2017 Jan 3;116(1):36-43.

Grossi F, **Rijavec E**, Genova C, Barletta G, Biello F, Maggioni C, Burrafato G, Sini C, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.

New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.

[2017]

Expert Opin Pharmacother. 2017 Jan;18(1):19-33.

Genova C, **Rijavec E**, Biello F, Rossi G, Barletta G, Dal Bello MG, Vanni I, Coco S, Alama A, Grossi F.

Vinflunine for the treatment of non-small cell lung cancer.

[2016]

Expert Opin Investig Drugs. 2016 Dec;25(12):1447-1455

Genova C, Alama A, Coco S, **Rijavec E**, Dal Bello MG, Vanni I, Biello F, Barletta G, Rossi G, Grossi F.

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.

[2016]

BMC Cancer. 2016 Aug 30;16:692.

Bonfiglio S, Vanni I, Rossella V, Truini A, Lazarevic D, Dal Bello MG, Alama A, Mora M, **Rijavec E**, Genova C, Cittaro D, Grossi F, Coco S.

Advances in treatment of mesothelioma.

[2016]

Expert Opin Pharmacother. 2016;17(9):1197-205.

Maggioni C, Barletta G, **Rijavec E**, Biello F, Gualco E, Grossi F.

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

[2016]

Lung Cancer 2016;95:73-81.

Valalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, **Rijavec E**, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.

Fibroblast Growth Factor Receptor (FGFR): A new target for non-small cell lung cancer therapy.

[2016]

Anticancer Agents Med Chem.2016;16(9):1142-54

Biello F, Burrafato G, **Rijavec E**, Genova C, Barletta G, Truini A, Coco S, Dal Bello MG, Alama A, Boccardo F, Grossi F.

Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.

[2016]

Microrna 2016;5(1):12-18.

Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, **Rijavec E**, Barletta G, Biello F, Maggioni C, Grossi F.

Hematopoietic growth factors in lung cancer.

[2016]

Curr Opin Oncol. 2016 Mar;28(2):135-44.

Genova C, **Rijavec E**, Grossi F.

Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.

[2015]

Dis Markers. 2015;2015:302649.

Grossi F, Dal Bello MG, Salvi S, Puzone R, Pfeffer U, Fontana V, Alama A, **Rijavec E**, Barletta G, Genova C, Sini C, Ratto GB, Taviani M, Truini M, Merlo DF.

Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.

[2015]

Int J Mol Sci. 2015 Dec 3;16(12):28765-82.

Vanni I, Coco S, Truini A, Rusmini M, Dal Bello MG, Alama A, Banelli B, Mora M, **Rijavec E**, Barletta G, Genova C, Biello F, Maggioni C, Grossi F.

Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.

[2016]

Expert Rev Anticancer Ther. 2016;16(1):1-4.

Genova C, **Rijavec E**, Grossi F.

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.

[2015]

Lung Cancer. 2015;90(2):234-42.

Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group.

Belagenpumatucel-L for the treatment of non-small cell lung cancer.

[2015]

Expert Opin Biol Ther. 2015;15(9):1371-9.

Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello M.G, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi M.A, Boccardo F, Grossi F.

Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.

[2015]

Int J Cancer. 2015;137 (12):2947-58.

Dal Bello Mg, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, **Rijavec E**, Biello F, Bottoni G, Sambuceti G, Grossi F.

Uncommon EGFR exon 19 mutations confer gefitinib resistance in advanced lung adenocarcinoma.

[2015]

J Thor Oncol. 2015;10(6):e50-52.

Coco S, Truini A, Vanni I, Genova C, Rosano C, Dal Bello MG, Alama A, Venè R, **Rijavec E**, Barletta G, Boccardo F, Grossi F.

Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.

[2015]

Curr Drug Targets. 2015;16(1):47-59

Coco S, Truini A, Vanni I, Dal Bello MG, Alama A, **Rijavec E**, Genova C, Barletta G, Sini C, Burrafato G, Biello F, Boccardo F, Grossi F.

Ramucirumab: preclinical research and clinical development.

[2014]

Onco Targets Ther. 2014 Oct 29;7:1997-2006

Aprile G, **Rijavec E**, Fontanella C, Rihawi K, Grossi F.

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to mesenchymal transition.

[2015]

Target Oncol. 2015 Sep;10(3):393-404

Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, **Rijavec E**, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, Grossi F.

Clinical applications of circulating tumor cells in lung cancer patients by CellSearch System.

[2014]

Front Oncol. 2014 Sep 4;4:242.

Truini A, Alama A, Dal Bello MG, Coco S, Vanni I, **Rijavec E**, Genova C, Barletta G, Biello F, Grossi F.

Efficacy of motesanib diphosphate in non-small-cell lung cancer.

[2014]

Expert Opin Pharmacother. 2014 Aug; 15(12):1771-80.

Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, Grossi F.

Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?

[2014]

Curr Med Res Opin. 2014 Nov;30(11):2291-3

Genova C, **Rijavec E**, Grossi F.

Oral vinorelbine in the treatment of non-small-cell lung cancer.

[2014]

Expert Opin Pharmacother. 2014 Aug; 15 (11):1585-99.

Barletta G, Genova C, **Rijavec E**, Burrafato G, Biello F, Sini C, Dal Bello MG, Coco S, Truini A, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F. .

Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.

[2014]

Expert Opin Biol Ther. 2014 Jul, 14 (7): 1007-17.

Rijavec E, Genova C, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F.

Afatinib for the treatment of advanced non-small-cell lung cancer.

[2014]

Expert Opin Pharmacother. 2014 Apr; 15(6):889-903.

Genova C, **Rijavec E**, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F.

Role of microRNAs in malignant mesothelioma.

[2014]

Cell Mol Life Sci. 2014 Aug;71(15):2865-78.

Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, **Rijavec E**, Burrafato G, Boccardo F, Grossi F.

Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.

[2014]

Future Oncol. 2014 Jan; 10(1):79-90.

Rijavec E, Genova C, Alama A, Barletta G, Sini C, Pronzato P, Coco S, Dal Bello MG, Savarino G, Truini A, Boccardo F, Grossi F.

Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients.

[2013]

Mol Cancer. 2013 Aug 29;12(1):97.

Puzone R, Savarino G, Salvi S, Dal Bello MG, Barletta G, Genova C, **Rijavec E**, Sini C, Esposito AI, Ratto GB, Truini M, Grossi F, Pfeffer U.

Pemetrexed for the treatment of non-small cell lung cancer.

[2013]

Expert Opin Pharmacother. 2013 Aug 14;(11):1545-58.

Genova C, **Rijavec E**, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F.

Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.

[2013]

Lung Cancer. 2013 Aug; 81(2):236-40.

Grossi F, Genova C, Gaitan ND, Dal Bello MG, **Rijavec E**, Barletta G, Sini C, Donato C, Beltramini S, Pronzato P, Porcile G, Boccardo F, Walzer S.

Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.

[2012]

Expert Opin Biol Ther. 2012 Jul;12(7):939-48.

Genova C, **Rijavec E**, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, Grossi F.

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

[2012]

Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12.

Grossi F, **Rijavec E**, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.

[2012]

Cancer Immunol Immunother. 2012 Sep;61(9):1463-72.

Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, **Rijavec E**, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP.

Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells.

[2007]

Anticancer Drugs 2007;18(8):883-8.

Puglisi F, Andreetta C, Valent F, Minisini AM, **Rijavec E**, Russo S, Mansutti M, Cardellino G, Pizzolitto S, Di Loreto C.

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.

[2021]

Int J Mol Sci. 2021 Apr 30;22(9):4774.

Indini A, Rijavec E, Grossi F.

COMPETENZE DIGITALI

Padronanza del Pacchetto Office (Word Excel PowerPoint ecc)

COMPETENZE PROFESSIONALI

ATTIVITA'

Attività clinica e partecipazione a gruppi multidisciplinari con focus sulle neoplasie toraciche. Attività di ricerca clinica. Collaborazione alla produzione di lavori scientifici.

Esperienza, in qualità di Principal Investigator e Sub Investigator, nella conduzione di studi clinici di fase II e III su neoplasie polmonari e mesotelioma pleurico (vedi elenco studi in cui ho svolto/svolgo ruolo di PI in Allegato 2)

DICHIARO DI ESSERE CONSAPEVOLE DELLE SANZIONI PREVISTE IN CASO DI DICHIARAZIONI NON VERITIERE

Dichiarazione

Il presente curriculum ha la funzione di autocertificazione ai sensi del D.P.R. 445/2000.

Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e dell'art. 13 del GDPR (Regolamento UE 2016/679).

Genova 8/5/2021